Prevalence of pre-existing direct-acting antiviral agents resistance-associated variants in genotype 1 HCV/HIV co-infected patients
10.3969/j.issn.1674-8115.2018.04.010
- Author:
Ling-Yu JIANG
1
Author Information
1. Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral, Chongqing Medical University
- Publication Type:Journal Article
- Keywords:
Co-infection;
Direct-acting antiviral agents;
Hepatitis C virus;
Prevalence;
Resistance associated variants
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2018;38(4):411-415
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the prevalence of pre-existing direct-acting antiviral agents (DAAs) resistance associated variants (RAVs) in genotype 1 hepatitis C virus (HCV)/ human immunodeficiency virus (HIV) co-infected patients. Methods: All NS3 and NS5B HCV sequences in genotype 1 HCV/HIV co-infected patients were retrieved from NCBI GenBank database. And sequences were aligned and analyzed using software MEGA 5.0. Results: In total, the overall prevalence of DAAs RAVs in NS3 region was high (26.06% and 38. 18%, respectively), no matter in genotype 1a or genotype 1b. In genotype 1a, the high prevalence of RAVs mainly presented in the position Q80 (8.45%). In genotype 1b, S122 RAV was most observed (36.36%). It is worth noting that, RAVs in NS5B region were rare observed (0.77%) in this study, especially as no RAV was detected in any sequence of genotype 1a patients. Conclusion: The prevalence of pre-existing RAVs is high in NS3 region but rare in NS5B region in HCV/HIV co-infected patients, suggesting that NS5B inhibitors based combination regions are a better choice for HCV/HIV co-infected patients.
